BILIARY ATRESIA

Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease ........................................... 11: 85-oa

Unusual cause of common bile duct dilatation in asymptomatic elderly patient: right hepatic artery syndrome ..................................... 11: 150-le

Intestinal nuclear bile acid receptor FXR and cholestasis ...................................... 11: 152-lne

Recurrent pyogenic cholangitis in a case with congenital biliary anomaly ..................... 11: 268-cr

Outcomes of choledochal cysts with or without intrahepatic involvement in children after extrahepatic cyst excision and Roux-en-Y hepaticejunoanastomosis ........................................ 11: 536-oa

Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanicular phospholipid and bile salt transporters ........................................ 11: 710-cr

Bile acids content in brain of common duct ligated rats ...................................... 11: 930-oa

BLEEDING VARICES

Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding ......................... 11: 369-oa

Can ARFI elastography predict the presence of significant esophageal varices in newly diagnosed cirrhotic patients? .............................. 11: 519-oa

Splenectomy in cirrhosis with hypersplenism: improvement in cytopenias, child’s status and institution of specific treatment for hepatitis C with success ........................................ 11: 921-oa

CIRRHOSIS

Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality ............................................. 11: 90-oa

Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis ............... 11: 100-oa

Acute kidney injury in critically ill cirrhotic patients: a review ..................................... 11: 301-cre

Hospital performance reports based on severity adjusted mortality rates in patients with cirrhosis depend on the method of risk adjustment .......... 11: 526-oa

Decreased serum total T3 level in hepatitis B and C related cirrhosis by severity of liver damage .............. 11: 667-oa

DIABETES

Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage ........................................ 11: 554-cr

HEPATIC

Hepatic dysfunction in children with tuberculosis on treatment with antituberculous therapy .... 11: 96-oa

Primary hepatic amyloidosis: a mini literature review and five cases report .................. 11: 721-cr

Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin .......................... 11: 77-oa

HEPATITIS

Intrafamilial seropositivity of hepatitis in patients with hepatitis B and C virus in hepatitis clinic in Hamadan, Iran ......................... 11:32-oa

Prevalence of hepatitis A, B and C serological markers in children from western Mexico ......... 11: 194-oa

Fulminant hepatitis during self-medication with conjugated linoleic acid ........................ 11: 265-cr

Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? .................. 11:320-oa

Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt ................................................. 11: 464-oa

Acute autoimmune hepatitis presenting with peripheral blood eosinophilia ..................... 11: 559-cr

Pegylated interferon, but not conventional interferon therapy induced severe skin lesions .......... 11: 570-le

Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India ........................................... 11: 870-oa

A

Hepatitis A vaccination in healthcare personnel ............................................ 11: 326-oa

Clinical course and management of acute hepatitis A infection in adults ...................... 11: 652-oa

B

Prevalence and resistance pattern of genotype G and H in chronic hepatitis B and HIV co-infected patients in Mexico ...................... 11: 47-oa

Hepatitis B viral load and risk of HBV-related liver disease: from East to West? ............. 11: 164-cre

Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B ........................................ 11: 202-oa

Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure .................. 11: 311-oa
Hepatitis B virus prevalence and vaccination response in health care workers and students at the Federal University of Bahia, Brazil .......... 11: 330-oa

Genotype/Subgenotype distribution of hepatitis B virus among hemodialysis patients with chronic hepatitis B ......................... 11: 849-oa

Epidemiological, clinical, and laboratory features of chronic hepatitis B infection in a cohort of immigrant and Italian patients from Ferrara, Italy .......... 11: 862-oa

C

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients .................................. 11: 15-oa

Serum lipids and chronic hepatitis C genotype 4: interaction and significance ........................................ 11: 37-oa

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial .......... 11: 52-oa

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT ........................................ 11: 186-oa


Successful antiviral treatment of chronic hepatitis C in patients with rare comorbidities. Two case-reports ........................................................................ 11: 404-cr

Does the persistently normal aminotransferase levels in hepatitis C still have relevance? .............................................. 11: 412-le

Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients ........................................ 11: 450-oa

The socioeconomic impact of hepatitis C infection and liver transplantation in Mexico ........................................ 11: 550-ed

Atherosclerosis and chronic hepatitis C ........................................ 11: 574-lne

The epidemiologic burden of hepatitis C virus infection in Latin America ........................................ 11: 623-cre

Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? ............... 11: 648-oa

Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects ......................... 11: 658-oa

Silybin/Silymarin treatment in chronic hepatitis C ........................................ 11: 731-lne

Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment ........................................ 11: 827-cre

HEPATOCARCINOGENESIS

Does the size of the needle influence the number of portal tracts obtained through percutaneous liver biopsy? ......................... 11: 691-oa

Inflammatory myofibroblastic tumor of the liver ........................................ 11: 708-ih

HEPATOCELLULAR CARCINOMA

Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes ........................................ 11: 118-oa

Cellular microRNA and the tumorigenesis of hepatocellular carcinoma .......... 11: 272-lne

Prevention of hepatocellular carcinoma: a concise review of contemporary issues ........................................ 11: 284-cre

Cardiac metastasis of hepatocellular carcinoma in a young non-cirrhotic patient, to the left ventricle ......................... 11: 392-ih

Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma ......................................... 11: 487-oa

Transforming growth factor a immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue ........................................................................ 11: 495-oa

Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma ........................................ 11: 899-oa

Thyroid-like cholangiocarcinoma of the liver: an unusual morphologic variant with follicular, trabecular and insular patterns ........................................ 11: 961-cr

HEPATOTOXICITY

Hepatotoxicity associated with statins ........................................ 11: 418-lne

Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement ........................................ 11: 500-oa

Hepatotoxicity associated with dietary energy supplements: use and abuse by young athletes ........................................ 11: 564-cr
Greater Celandine hepatotoxicity: a clinical review ........................................ 11: 838-cre
Protective role of standardized *Feronia limonia* stem bark methanolic extract against carbon tetrachloride induced hepatotoxicity .............. 11: 935-oa
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population .................. 11: 700-oa

**HYPERTENSION**

Massive avascular malformations causing life threatening portal hypertension ........................................ 11: 552-ih
Idiopathic portal hypertension with multiple hepatic hyperplastic nodules supplied by portal vein ...... 11: 572-le

**LIVER**

Shark liver oil: hidden dangers ........................................ 11: 728-le
Abnormal liver function tests in a patient with myotonic dystrophy type 1 ........................................ 11: 130-cr
Acute liver failure due to non-exertional heatstroke after sauna ...................................................... 11: 138-cr
Evidence for liver injury in the setting of obstructive sleep apnea .................................................. 11: 228-oa
Increased mortality from acute liver failure in Mexico .... 11: 257-oa
Portal vein aneurysm: is it an incidental finding only? ...... 11: 263-ih
Treatment of hyperferritinemia ........................................ 11: 294-cre
Association between butyrylcholinesterase activity and low-grade systemic inflammation .............. 11: 356-oa
Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats .... 11: 384-oa
Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice ............... 11: 426-cre
Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative .......... 11: 544-ed
Role of nitric oxide in liver regeneration ........................................ 11: 636-cre
An unusual cause of portal cavernomatosis .................. 11: 949-ih
Spontaneous bacterial peritonitis caused by *Listeria monocytogenes*: a case report and literature review .................. 11: 955-cr

**LIVER DISEASE**

Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis .......... 11: 7-cre
Serum homocysteine levels in patients with nonalcoholic fatty liver disease ........................................ 11: 68-oa

Amoebic liver abscess production by *Entamoeba dispar* .. 11: 107-oa
High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity ...................... 11: 350-oa
Living *Fascial hepatica* in biliary tree: a case report .... 11: 395-cr
Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases .......... 11: 399-cr
Acetylcholinesterase and butyrylcholinesterase as markers of low-grade systemic inflammation .............. 11: 409-le
Risk factors for in-hospital mortality of patients with high model for end-stage liver disease scores following living donor liver transplantation .......... 11: 471-oa
Polycystic liver disease: a clinical review .................. 11: 819-cre
Alcohol effects on liver diseases: good or bad buddy? .... 11: 944-ed

**NONALCOHOLIC FATTY LIVER DISEASE**

Is it appropriate to study blood ghrelin and obestatin in non-alcoholic fatty liver disease (NAFLD) without using protease inhibitors? ........................................ 11: 145-le
Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease? ...................... 11: 147-le
Transient elastography in non-alcoholic fatty liver disease ........................................ 11: 172-cre
Gut microbiota and nonalcoholic fatty liver disease ...... 11: 440-cre
Correlation of adipose tissue with liver histology in Asian Indian patients with nonalcoholic fatty liver disease (NAFLD) .............. 11: 478-oa

**PERITONITIS**

Rapid diagnosis of spontaneous bacterial peritonitis using leukocyte esterase reagent strips in Emergency Department: Uri-Quick Clini-10SG® vs. Multistix 10SG® .................. 11: 696-oa
Prognostic factors associated with in-hospital mortality in patients with spontaneous bacterial peritonitis .................. 11: 915-oa
Glisson’s capsule blistering after hyperthermic intraperitoneal chemotherapy .................. 11: 128-ih

**SYNDROME**

Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis .......... 11: 143-le
Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1 .................. 11: 232-oa
Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome .......... 11: 343-oa
STUDIES

Region 11 MELD Na exception prospective study .............. 11: 62-oa

Prognostic markers in cirrhotic patients requiring intensive care:
a comparative prospective study .............................. 11: 513-oa

Response to different therapeutic approaches in Wilson disease.
A long-term follow up study ................................. 11: 907-oa

Epidemiologic trends in HBV infections at a reference centre in Turkey:
an 11-year retrospective analysis ............................. 11: 672-oa

The prevalence and clinical characteristics of glucose metabolism disorders in patients
with liver cirrhosis. A prospective study ....................... 11: 240-oa

A comparison study of local injection and radiofrequency ablation therapy for traumatic
portal vein injury guided by contrast-enhanced ultrasonography ......................... 11: 249-oa

Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study ....................... 11: 364-oa

THROMBOSIS

A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients ......................... 11: 686-oa

TRANSPLANTATION

A review of drug interactions with boceprevir and telaprevir:
implications for HIV and transplant patients ................ 11: 179-cre

Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report ....................... 11: 951-cr

Primary hepatic neuroendocrine tumour requiring live donor liver transplantation:
case report and concise review ................................. 11: 715-cr

Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease ..................... 11: 213-oa

Liver transplantation for autoimmune hepatitis in Peru: outcomes and recurrence .................. 11: 222-oa

Causes of death after liver transplantation ...................... 11: 415-le

Liver transplantation in the critically ill: donation after cardiac death compared
to donation after brain death grafts .............................. 11: 679-oa

Health-related quality of life in Egyptian patients after liver transplantation .................. 11: 882-oa

Steatotic livers. Can we use them in OLTX?
Outcome data from a prospective baseline liver biopsy study ............................................. 11: 891-oa

An unusual cause of cancer mimicry following liver transplantation ....................... 11: 134-cr